Finmark Laboratories
Veterinary biotechnology company focused on research, formulation and production of vaccines and related biotechnological products for poultry and livestock. Activities include development and industrial production of inactivated bacterin and toxoid vaccines, use of molecular biology and bioinformatics for antigen selection, probiotic and immunomodulator formulation, molecular typing services, and collaborations with research institutions. The company states adherence to internal quality standards and maintains distributor partnerships.
Industries
Nr. of Employees
small (1-50)
Finmark Laboratories
Zipaquirá, Cundinamarca, Colombia, South America
Products
Multivalent clostridial and pasteurella vaccines for ruminants
Inactivated bacterin and toxoid formulations targeting multiple Clostridium species and Pasteurella multocida for bovines, ovines and caprines; provided in multiple vial sizes.
Inactivated poultry bacterin vaccines (Salmonella, Pasteurella, Avibacterium, Gallibacterium, E. coli)
Adjuvanted inactivated bacterin vaccines formulated to prevent Salmonellosis, Pasteurellosis, infectious coryza and colibacillosis in breeder and layer poultry.
Combined multivalent vaccines for bovines, ovines and caprines
Bacterin/toxoid combinations covering multiple clostridial species and other bacterial pathogens for herd immunization schedules.
Botulism toxoid vaccines for ruminants
Toxoid formulations against Clostridium botulinum serotypes relevant for prevention of botulism in cattle, sheep and goats.
Multivalent poultry vaccines for respiratory and enteric pathogens
Formulations combining protection against Avibacterium paragallinarum, Pasteurella multocida, Salmonella spp., Gallibacterium and related pathogens for breeder and layer birds.
Multivalent clostridial and pasteurella vaccines for ruminants
Inactivated bacterin and toxoid formulations targeting multiple Clostridium species and Pasteurella multocida for bovines, ovines and caprines; provided in multiple vial sizes.
Inactivated poultry bacterin vaccines (Salmonella, Pasteurella, Avibacterium, Gallibacterium, E. coli)
Adjuvanted inactivated bacterin vaccines formulated to prevent Salmonellosis, Pasteurellosis, infectious coryza and colibacillosis in breeder and layer poultry.
Combined multivalent vaccines for bovines, ovines and caprines
Bacterin/toxoid combinations covering multiple clostridial species and other bacterial pathogens for herd immunization schedules.
Botulism toxoid vaccines for ruminants
Toxoid formulations against Clostridium botulinum serotypes relevant for prevention of botulism in cattle, sheep and goats.
Multivalent poultry vaccines for respiratory and enteric pathogens
Formulations combining protection against Avibacterium paragallinarum, Pasteurella multocida, Salmonella spp., Gallibacterium and related pathogens for breeder and layer birds.
Services
Collaborative research and development
R&D collaborations with universities, public and private research centers to develop and validate vaccine technologies and related biotechnological products.
Molecular typing and analytical support
Molecular typing programs for prokaryotes to support diagnostic, epidemiological and R&D activities.
Technical support and product use guidance
Guidance on vaccine dosing, administration routes and revaccination schedules for poultry and livestock.
Collaborative research and development
R&D collaborations with universities, public and private research centers to develop and validate vaccine technologies and related biotechnological products.
Molecular typing and analytical support
Molecular typing programs for prokaryotes to support diagnostic, epidemiological and R&D activities.
Technical support and product use guidance
Guidance on vaccine dosing, administration routes and revaccination schedules for poultry and livestock.
Expertise Areas
- Veterinary vaccine development
- Vaccine formulation and manufacturing
- Molecular biology and bioinformatics
- Probiotic and prebiotic development
Key Technologies
- Iron-restricted outer membrane protein expression (IROMPs)
- Formaldehyde antigen inactivation
- Aluminum-hydroxide adjuvant formulations with polymer carriers
- Inactivated bacterin and toxoid vaccine platforms